|A unique collection of 81 Cardioprotective natural compounds for high throughput screening (HTS) and high content screening (HCS).|
|Catalog No:||Bb1313|| Cardioprotective Compound Library
|Size:||1mg/well * 81 Compounds|
2mg/well * 81 Compounds
1. Ursolic acid has antidepressant-like activity.
2. Ursolic acid may have a potential application as a chemopreventive agent to prevent the metastasis of gastric cancer or to alleviate the process of metastasis.
3. Ursolic acid may ameliorate colitis by regulating NF-κB and MAPK signaling pathways via the inhibition of LPS binding to TLR4 on immune cells.
4. Ursolic acid has hepatoprotective action, can inhibit CCl4-induced liver fibrosis, inflammation and apoptosis, via at least in part to its ability to modulate the Nrf2/ARE signalling pathway.
5. Ursolic acid inhibits Hut-78 cells' proliferation and induced apoptosis through h death receptors and mitochondrial pathways, NF-κB classical signal pathway may be one of its mechanisms, and VEGF and cox-2 may also be involved.
1. Visnagin has anti-inflammatory effect , might result from the inhibition of transcription factors, such as AP-1 and NF-κB.
2. Visnagin and diphenylurea are potent cardioprotective compounds, and MDH2 is a previously undescribed, druggable target for doxorubicin-induced cardiomyopathy.
1. Rutaecarpine has the potential for use as an anti-atherosclerosis agent with a novel mechanism.
2. Rutaecarpine promotes glucose consumption and improves insulin resistance possibly through suppression of inflammatory cytokines in the IR-PSMC cells.
3. Rutaecarpine is effective against Ang II-induced rat VSMC proliferation, at least in part, to NO production and the modulation of VMSC proliferation-related gene expressions.
1. Nardosinone has inhibitory effect on Ang II-induced hypertrophy in H9c2 cells, might be mediated by targeting PI3K/Akt and MEK/ERK signaling pathways.
2. Nardosinone could protect against the neuronal injury exposed to OGD, which may be relevant to the promotion of PKA and ERK signaling pathway.
3. Nardosinone enhances staurosporine- or dbcAMP-induced neurite outgrowth from PC12D cells, probably by amplifying both the MAP kinase-dependent and -independent signaling pathways of dbcAMP and staurosporine.
4. The enhancement of NGF-induced neurite outgrowth from PC12D cells by Nardosinone involves activation of a down-stream step of the MAP kinase-dependent cascade of NGF coupled with PKC.
1. Glaucocalyxin A-SBE-β-CD could be useful with a better solubility and sustained function in drug delivery.
2. Glaucocalyxin A activates caspase-3, decreases BAD phosphorylation, and reduces the expression of X-linked inhibitor of apoptosis protein.
3. Glaucocalyxin A inhibits Akt phosphorylation, suppresses proliferation, and promotes apoptosis in a dose-dependent manner, but not in normal glial cells.
4. Glaucocalyxin A inhibits collagen-stimulated tyrosine phosphorylation of Syk, LAT, and phospholipase Cγ2, the signaling events in collagen receptor GPⅥ pathway.
5. Glaucocalyxin A could potentially be developed as an antiplatelet and antithrombotic agent, can inhibit platelet p-selectin secretion and integrin activation by convulxin, is a GPVI selective ligand.